IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial
IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial
Read moreFri, 20th Dec 2019 15:48
IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial
Read moreAIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%
Read moreUK earnings, trading statements calendar - next 7 days
Read moreAIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks
Read moreIN BRIEF: Hutchmed tumor drug qualifies for formal review by EU agency
Read more(Sharecast News) - Hutchmed China announced the first commercial sale in China of 'Orpathys', or savolitinib, on Tuesday, which is its "oral, potent, and highly-selective" small molecule inhibitor of MET, a receptor tyrosine kinase.
Read moreTRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows
Read moreTRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays
Read moreTRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free
Read moreTRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy
Read moreIN BRIEF: Hutchmed launches global offering for 104 million shares
Read moreIN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China
Read moreIN BRIEF: Hutchmed launches Hong Kong IPO; drug candidate approved
Read more(Sharecast News) - Hutchmed China announced the launch of its Hong Kong public offering on Friday, as part of its global offering of 104 million new shares, proposing the primary listing of its ordinary shares on the main board of the Hong Kong Stock Exchange under the stock code '13'.
Read moreTRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan
Read more